MDGL vs TECH: Madrigal Pharmaceuticals and Bio-Techne compared
The short version
From the latest prices and each company's SEC filings. Who's ahead on each measure, not which to buy.
- Bio-Techne is the larger company, worth $11.5B, close to Madrigal Pharmaceuticals's $10.7B.
- Madrigal Pharmaceuticals grew revenue faster over the last year (+71.2% vs +1.3%).
- Bio-Techne keeps more of each dollar of revenue as operating profit (20.7% vs -25.1%).
Side by side
The stronger figure is shaded where higher (or, for valuation multiples, lower) reads as better. How the implied growth works.
| Measure | MDGL | TECH |
|---|---|---|
| Market cap | $10.7B | $11.5B |
| Share price | $471.75 | $72.46 |
| Revenue (last fiscal year) | $958M | $1.2B |
| Free cash flow (last fiscal year) | -$190M | $263M |
| Revenue growth, last year | +71.2% | +1.3% |
| Revenue growth per year, last 5 fiscal years | — | +2.4% |
| Operating margin | -25.1% | 20.7% |
| Net margin | -25.3% | 15.0% |
| Return on equity | -62.1% | 8.6% |
| P/E (trailing) | — | 104.9x |
| Price / free cash flow | — | 44.8x |
| EV / EBITDA | — | 32.3x |
| FCF growth the price implies | — | 15.2% |
| Dividend yield | — | 0.45% |
| Debt / equity | 1.38x | 0.23x |
| Fundamental grade | D | C |
| Superinvestors holding it | 3 | 10 |
| Insider purchases, last 12 months | 0 | 10 |
Results from SEC filings
Revenue and free cash flow by fiscal year, from each company's 10-K filings.
Madrigal Pharmaceuticals
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $0 | -$184M | — |
| 2022 | $0 | -$225M | — |
| 2023 | $0 | -$326M | — |
| 2024 | $180M | -$457M | -276.4% |
| 2025 | $958M | -$190M | -31.3% |
Bio-Techne
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2022 | $1.1B | $280M | 26.8% |
| 2023 | $1.1B | $216M | 26.3% |
| 2024 | $1.2B | $236M | 17.8% |
| 2025 | $1.2B | $257M | 8.4% |
| 2026 | $1.2B | $263M | 20.7% |
Where the revenue comes from
Madrigal Pharmaceuticals
No segment breakdown reported.
Bio-Techne · by segments, 2024
Protein Sciences$831M72%
Diagnostics and Spatial Biology$326M28%
Compare them in fullFifteen years of statements, quarterly results, DCF and IRR models, and any number of peers side by side.
Open MDGL in InvestinglyQuestions
Which is bigger, Madrigal Pharmaceuticals or Bio-Techne?
Bio-Techne (TECH), at $11.5B against $10.7B.
Which grows faster, MDGL or TECH?
Madrigal Pharmaceuticals: revenue grew +71.2% over the last year, against +1.3%.
More comparisons
Prices and ratios as of the last daily update; statements from SEC filings. Information only, not investment advice.